By Siddhi Mahatole
(Reuters) -Women’s telehealth provider Wisp said on Wednesday it has expanded its weight-care offerings to include sale and doorstep delivery of Novo Nordisk’s and Eli Lilly’s wildly popular drugs without the need for insurance.
Telehealth firms, along with the two drugmakers, pharmacies, and other related entities, have launched several direct-to-consumer offerings to tap into the extraordinary demand for weight-loss drugs.
New York-based Wisp said it has priced Ozempic, Wegovy, and Mounjaro at $598, $558, and $489 per month, respectively, with the cost also including consultation, monthly follow-ups, and direct-to-door delivery.
U.S. list prices for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are about $1,000 per month or more. But both companies offer a monthly supply for $499 to customers paying cash instead of using health insurance.
“Our cash-pay model particularly benefits those who would otherwise face high out-of-pocket costs or who wouldn’t qualify for coverage of GLP-1s,” CEO Monica Cepak told Reuters in an email.
Wisp, majority-owned by Canada-based digital healthcare firm WELL Health Technologies, launched its weight care vertical in 2024, initially addressing hormonal imbalances from conditions like PCOS and menopause. The telehealth firm plans further expansion into at-home diagnostics and menopause care.
Other telehealth providers offering GLP-1 medications include Hims & Hers, LifeMD, Teladoc Health, Ro, and Noom Med, many of which partner with drugmakers to provide FDA-approved treatments alongside health coaching and weight management support.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Leroy Leo)
Comments